Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGR NASDAQ:BBLG NASDAQ:IVF NYSE:SONX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.41 million shsN/ABBLGBone Biologics$2.90+0.7%$4.50$2.86▼$25.50$1.58M0.69352,226 shs71,523 shsIVFINVO Fertility$0.80+1.6%$1.28$0.74▼$17.04$1.70M2.04577,463 shs65,929 shsSONXSonendo$1.15$1.24$1.00▼$17.00$493K1.51,012 shsN/A10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-73.22%BBLGBone Biologics+0.69%-2.03%-38.75%-27.89%-59.04%IVFINVO Fertility+1.65%-5.66%-38.79%+80,189,900.00%+80,189,900.00%SONXSonendo0.00%0.00%0.00%-7.26%+1,431.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/ABBLGBone Biologics0.9112 of 5 stars0.02.00.00.03.80.01.3IVFINVO FertilityN/AN/AN/AN/AN/AN/AN/AN/ASONXSonendoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/ABBLGBone Biologics 0.00N/AN/AN/AIVFINVO Fertility 0.00N/AN/AN/ASONXSonendo 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10BBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/AIVFINVO Fertility$6.53M0.27N/AN/A($29.86) per share-0.03SONXSonendo$44.40M0.01N/AN/A$89.42 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)BBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)IVFINVO Fertility-$9.10M-$34.06N/A∞N/A-377.73%N/A-88.18%N/ASONXSonendo-$60.92M-$59.12N/A∞N/A-92.74%-184.01%-68.60%8/8/2025 (Estimated)Latest SONX, IVF, BBLG, and AVGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025N/ABBLGBone Biologics-$1.93N/AN/AN/AN/AN/A5/20/2025Q1 2025IVFINVO FertilityN/A-$12.53N/A-$12.53N/A$1.64 million5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/ABBLGBone BiologicsN/AN/AN/AN/AN/AIVFINVO FertilityN/AN/AN/AN/AN/ASONXSonendoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/AN/AN/ABBLGBone BiologicsN/A12.6012.60IVFINVO FertilityN/A0.080.07SONXSonendo0.551.821.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%BBLGBone Biologics34.30%IVFINVO Fertility12.02%SONXSonendo28.68%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%BBLGBone Biologics7.50%IVFINVO Fertility0.57%SONXSonendo7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableBBLGBone Biologics2545,000504,000Not OptionableIVFINVO Fertility102.16 million2.15 millionN/ASONXSonendo250429,000393,000Not OptionableSONX, IVF, BBLG, and AVGR HeadlinesRecent News About These CompaniesSonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial GuidanceJune 4, 2025 | businesswire.comSonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | businesswire.comSonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024November 11, 2024 | businesswire.comSonendo, Inc. (SONX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseNovember 5, 2024 | zacks.comSonendo Launches ProControlTM for the GentleWave® G4 SystemOctober 23, 2024 | businesswire.comSonendo, Inc. Announces Preliminary Third Quarter 2024 Financial ResultsOctober 10, 2024 | businesswire.comBIOLASE files for Chapter 11, plans asset sale to SonendoOctober 3, 2024 | investing.comHere's Why Sonendo (SONX) Is a Great 'Buy the Bottom' Stock NowAugust 27, 2024 | zacks.comSonendo Inc.August 17, 2024 | marketwatch.comSonendo, Inc. (SONX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comSonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2024 | zacks.comSonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue GuidanceAugust 7, 2024 | finance.yahoo.comHere's what Wall Street expects from Sonendo's earnings reportAugust 7, 2024 | markets.businessinsider.comSonendo, Inc. (SONX)July 28, 2024 | finance.yahoo.comSonendo Strengthens Leadership With Key Strategic AppointmentsJune 5, 2024 | businesswire.comSonendo to Present at the 2024 Stifel Jaws & Paws ConferenceMay 20, 2024 | businesswire.comSonendo, Inc. (SONX) Q1 2024 Earnings Call TranscriptMay 12, 2024 | seekingalpha.comSonendo, Inc. (NYSE:SONX) Q1 2024 Earnings Call TranscriptMay 12, 2024 | msn.comSonendo Inc (SONX) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and Financial ...May 9, 2024 | finance.yahoo.comSONX Stock Earnings: Sonendo Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSONX, IVF, BBLG, and AVGR Company DescriptionsAvinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 07/1/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Bone Biologics NASDAQ:BBLG$2.90 +0.02 (+0.69%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.90 0.00 (0.00%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.INVO Fertility NASDAQ:IVF$0.80 +0.01 (+1.65%) As of 07/15/2025 04:00 PM EasternNAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. Our hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 and NKp46 targeting bispecific antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase I/II monotherapy trial in early 2025, NY-338, a CD38 and NKp46 targeting bispecific antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, and INVOcell®, an FDA-approved fertility device which has demonstrated comparable success rates to traditional In Vitro Fertilization (IVF).Sonendo NYSE:SONX$1.15 0.00 (0.00%) As of 07/14/2025Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
